Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent

1. A method of concurrent imaging of organ blood flow and vitronectin receptors sites in a mammal comprising:

I) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and

II) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and

III) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent;

wherein the vitronectin receptor targeted imaging agent is a diagnostic metallopharmaceutical comprising 111 In, and a compound comprising:

a) a chelator which is DOTA (1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecane); and

b) a targeting moiety which is bound to the chelator and is (2S)-2-[({2,6-dimethyl-4-(4-butoxyoyl)phenyl}sulfonyl)amino]-3-({7-[(imidazol-2-ylamino)methyl)]-1-methyl-4-oxo(3-hydroquinolyl)}-carbonylamino) propanoic acid; and

c) a linking group between the targeting moiety and the chelator, which is 2-(2-aminoethylcarbonyl)-2-(2-amino-3-sulfo-propanoylamino)-ethanesulfonic acid;

and wherein the perfusion imaging agent is 99m Tc sestamibi.

2. The method of claim 1 , wherein the images are displayed side-by-side to facilitate interpretation of the localization of the vitronectin targeted imaging in the body, relative to the distribution of the perfusion agent in the body.

3. The method of claim 1 , wherein the images are overlayed to facilitate interpretation of the localization of the vitronectin targeted imaging in the body, relative to the distribution of the perfusion agent in the body.

4. The method of claim 1 , for use in concurrent imaging sites of angiogenesis and organ perfusion.

5. The method of claim 1 , for use in diagnosing and localizing sites of angiogenesis and perfusion abnormalities.

6. The method of claim 1 , for use in concurrent detection and localization of sites of endothelial damage and perfusion abnormalities.

7. The method of claim 1 , for use in the concurrent detection and localization of sites of vulnerable plaque and perfusion abnormalities.

8. The method of claim 1 , wherein administering the vitronectin targeted imaging agent and a perfusion imaging agent is concurrent.

9. The method of claim 1 , wherein administering the vitronectin targeted imaging agent and a perfusion imaging agent is sequential.

10. The method of claim 1 , wherein the vitronectin targeted imaging agent and a perfusion imaging agent are administered in a synergistically effective amount.

11. The method of claim 1 , wherein the gamma-emission energies of the vitronectin targeted imaging agent and the perfusion imaging agent are spectrally separable by pulse-height analysis.

12. The method of claim 1 , wherein the difference in gamma emission spectral energies of the vitronectin antagonist diagnostic metallopharmaceutical and the perfusion imaging agent is >10 Kev.

13. The method of claim 1 , wherein the concurrent detection of the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent, is by dual isotope imaging.